Keros Therapeutics Inc. (KROS)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.
Keros Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 230 | $3,309.4 | $2,298.85 | -$1,010.55 | -30.54% |
| NA Nizar Araji National Bank Of Canada /FI/ | 30 | $828.9 | $334.5 | -$494.4 | -59.65% |
| RAD Robert A. Dee AMERICAN FINANCIAL GROUP Inc. | 10,105 | $429,000 | $107,517.2 | -$321,482.8 | -74.94% |
 Point72 Asset Management LP Point72 Asset Management LP | 10,393 | $114,738.76 | $104,969.3 | -$9,769.46 | -8.51% |
 Madison Avenue Partners LP Madison Avenue Partners LP | 626,583 | $8.41M | $6.33M | -$2.08M | -24.72% |
Keros Therapeutics Inc. (KROS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Keros Therapeutics Inc. ever had a stock split?
Keros Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jasbir S. Seehra CEO | NASDAQ (NMS) Exchange | 492327101 CUSIP |
| US Country | 92 Employees | - Last Dividend | - Last Split | 8 Apr 2020 IPO Date |
Overview
Keros Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. It specializes in addressing disorders related to the dysfunctional signaling of the transforming growth factor-beta family of proteins. Operating within the United States, the company is dedicated to serving patients with conditions that currently have limited treatment options. Established in 2015 and with its headquarters in Lexington, Massachusetts, Keros Therapeutics has emerged as a key player in the realm of biopharmaceuticals, aiming to revolutionize treatments for various health conditions through groundbreaking research and development efforts.
Products and Services
- KER-050
Primarily focusing on the treatment of low blood cell counts, or cytopenias, KER-050 is Keros Therapeutics' lead product candidate. This includes targeting conditions such as anemia and thrombocytopenia in patients with myelodysplastic syndromes and myelofibrosis. The ambition behind KER-050 is to provide relief and a potentially transformative treatment to patients dealing with these debilitating blood disorders.
- KER-012
Currently in Phase II clinical trial, KER-012 is being developed to treat pulmonary arterial hypertension and cardiovascular disorders. This formulation stands as a testimony to Keros Therapeutics' commitment to addressing complex cardiovascular diseases with the potential to significantly impact the quality of life for patients suffering from these conditions.
- KER-065
KER-065 has reached the Phase I clinical trial stage, and is aimed at the treatment of obesity and neuromuscular diseases. Through the development of KER-065, Keros Therapeutics is venturing into therapy areas that are crucial for improving the health and well-being of individuals afflicted by these widespread, yet challenging, health issues.
In addition to these products, Keros Therapeutics has established a collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. This agreement is focused on the development, manufacture, and commercialization of KER-050 and licensed products containing KER-050, highlighting the company's strategy of partnering to enhance and expedite the availability of its innovative treatments to patients worldwide.
